they're the larger names, namely gilead and celgene. they were barely up today because they're way too big to be taken over. they rallied like crazy earlier and then got clotheslined. gilead $6.50 off its 52-week high. celgene is $13 off its high. got a cancer drug that actually rivals onyx. it's selling for only 17 times next year's earnings estimates and has a 22% growth rate. gilead sells at an absurdly low 17 times earnings. so let me give you the bottom line. risk/reward matters. onyx pharma up 43 today after it rejected amgen's takeover bid. the most bullish estimate, bernstein. $50 from where it is now. if something goes wrong and no one decides to buy onyx and in retrospect, it turns out saying no to amgen was a mistake, the stock can get hammered. you've got to ring the register on onyx. if you want to still own it, you can only play with the house's money. there are other biotechs that i like more, that are simply better opportunities. seattle genetics, immunogen for speculative anticancer play similar to onyx. celgene and gil

like a celgene, like a biogene. amazon also reports thursday. like netflix, this is a cult stock. what does that mean, really? simple. it really doesn't mean -- it doesn't really mean that amazon's earnings necessarily matter. yeah, not kidding. only netflix and amazon have this bizarre quality. unless they tell you they're never make money ever or they're going it burn all the money in a chimney, people seem to be happy with it. the best trade, by the way, is to buy the stock earlier. weakness equals buy. last but not least, we get a housing checkup on friday. has housing been hurt by the spike in mortgage rates? my trust owns two stocks that i'm following closely, stanley works, the fantastic tools company, and warehouse, a home builder and lumber company. john paulson made billions betting against housing six years ago. now he's the biggest housing bull in the land. these are two the housing ones out there. if rates go up again between now and friday, these stocks will sell off no matter what they say. let's keep an eye out for them. here's the bottom line. there's a lot happen

what's the celgene news today? >> oh, my! it looks like celgene will go back. they have good data on multiple myeloma which is a cause you know well. bob came on "mad money," the stock had to pull their application. the stock went down 11%. he came on "mad money" and said we will be back. the stock has not only doubled, but i think his application will be accepted in europe for frontline. maybe it doesn't go in a straight line, but it does go. >> do you think to the degree it ever witness away the celgene trades and the trades are as high as they have been. >> it start at 51 and goes on 55 on no real news, but it's just terrific. regeneron, one of my absolute favorites. this group is back on fire and a terrific group to buy when interest rates go down. >> yeah. interestingly, but we have a couple of extra seconds. for instance, yesterday we had best buy getting taken to the wood shed. it's been doing great all year. does that happen to all of the names that have outperformed at some point? >> i think the analysts and everybody is so used to getting beat around

celgene and gilead have been downright unstoppable, taking out the old highs. i get that with celgene. they announced they would be able to reapply in europe. but gilead, nothing special at all. when we were all fretting and worrying, the two stocks are regarded as the most expensive large cap equities in the universe. amazon and netflix. now, when i was starting my old hedge fund, i used to go after these kinds of stocks. every time we had an interest rate spike, i shortened them with abandon, betting the price earned multiple i'd be coining money. but once rates stabilized, you were history and the shorts that did these trades this time around, they are, indeed, history. amazon, netflix, 52-week highs today. good shorts spoiled! of course, there are some stocks that haven't come back. housing stocks haven't, they need mortgage rates down to get them back. but if rates go down, they will go up. blackberry, united parcel, coca-cola, more on that later. they're disappointed where they are right now. they're in, yes, indeed, the bow wow chateau. but for the botto

celgene has anointed this and who am i that the fabulous ceo offal gene doesn't plan to sell. this is another one where if you can get a piece of the deal, i expe the first day of trading to be great, but then let the rest ride. i know, highly unusual for us, but the biotechs have been more than one-day wonders and finally there's been an intriguing one. energy, energy, yes, the big utility is doing a spin-off on wednesday. energy yield that i think is worth checking out. unity ipo, a youngster, utility ipos had the best week of all stocks. people now see these stocks as bond market equivalents vulnerable to interest rates rising. however, energy has held up and the stock is currently at a 52-week high and the dividend vehicle and the plan is for the company to support a 6% yield and now i can't bust this ipo on the current environment, but it is absolutely worth watch to see if the mark has saved it over the high yielders here's the bottom line. we have three sexy ipos coming over the next two weeks that are worth getting a piece of that i want you in. >> buy, buy, buy. >> re

celgene has anointed this and who am i that the fabulous ceo offal gene doesn't plan to sell. this is another one where if you can get a piece of the deal, i expect the first day of trading to be great, but then let the rest ride. i know, highly unusual for us, but the biotechs have been more than one-day wonders and finally there's been an intriguing one. energy, energy, yes, the big utility is doing a spin-off on wednesday. energy yield that i think is worth checking out. unity ipo, a youngster, utility ipos had the best week of all stocks. people now see these stocks as bond market equivalents vulnerable to interest rates rising. however, energy has held up and the stock is currently at a 52-week high and the dividend vehicle and the plan is for the company to support a 6% yield and now i can't bust this ipo on the current environment, but it is absolutely worth watch to see if the mark has saved it over the high yielders here's the bottom line. we have three sexy ipos coming over the next two weeks that are worth getting a piece of that i want you in. >> buy, buy, buy. >>

from gilead, from celgene, these were remarkable numbers we saw and i have to tell you something, in each case, i think these stocks are not done. they will now be the favorite stocks of the second half of 2013. i would not take profits. there's always a bull market somewhere. i'm jim cramer, see you tomorrow. the jersey mob does business the way the mob has always done business -- whatever it takes. >> if you have to kill somebody, you have to kill them. >> narrator: because in this world, where salesmen carry guns and the marketing strategy is cooperate or die, there's millions to be made. >> the basic principle is fear. "if you don't cooperate with us, well, things can happen." >> narrator: new jersey's decavalcante family knows how to make big money. and for better or worse, no one knows much about them, until a television series about a new jersey mob changes everything. >> they viewed themselves as the models for "the sopranos." >> narrator: but these mobsters

. >> celgene, yes, bob did tell us that would happen last year on the set when stock was in the 60s. it's doubled. gilead, biogen idec and regeneron. four stocks, i've been saying all of 2013. now, a big pipeline and i particular want you to keep your eye on conomid and a big early stage pipeline. also check out envision health care holdings, the largest ambulance service company in the u.s. how about the strength in tech ipos quarter? a lot of the best were enterprise software companies. what i like to think of as salesforce.com, i told you it was coming back. keep an eye out for more of these software as service companies. i like this one, it's called retail me not. you know, like retail me, retail me not. coupon marketplace. two growth names i already mentioned, as well as sea world, which i told you to get a piece of before it came public. here, i want to you to keep an eye out for the upcoming nieman marcus ipo, as well as sprouts. now, before we go over the worst performers, i liked the housing ipos, but interest rates spiked in the second quarter. while i still believe in hous

tuesday morning celgene reports. there's so many drugs in the pipeline the second half of the year. be prepared to hear numbers being raised on this very inexpensive stock. even after this doubled over the last 12 months, it was strong today along with this whole incredible cohort as the group's been most in favor i've ever seen. what a group. also thursday, we hear from 3m, which is the second biggest group to have an amazing run this year after boeing. this is a trading philosophy. if you bought some of this stock when 3m reported last time and got hammered -- but you know what, i don't know. you're an going to have to buy it back at lower levels. 3m has a big business. if you're talking to the ceo last night on the show and reading many reports of the continuing weakness in china, i'm getting a little nervous ahead of the quarter. they got a big asian business. even as i remain bullish long term about this fantastic, well-managed company. one of my favorites are, bristol-myers. this quintessential secular growth stock should give you a good read on its cancer pipeline. this is lo

i only recognized that because celgene is down the block from me. and also because my mom died of kidney cancer, personal insight that drew me to onyx's franchise, which is a breakthrough drug for kidney cancer. which has been a death sentence for many before this. and noodles and company, when it started trading, it hasn't looked back. it's infuriating to me. i'm blaming the fact i missed this in the parlor game of international finance. there was too much going on and i was too worried about the ten year. i knew that noodles might be the hottest concept out there. you can't even get into the joint. "new york times" say the hottest trend around is noodles. i know the chipotle chop house noodle business seems stillborn but the concept is a winning one. the ipo itself, hey, lost in the thick of the hand wringing over whether the fed was tightening or not. although my colleague herb greenberg does point out that noodles may not have the same store sales growth that the bulls are looking for. the money has been made, including today's $8.73 run-up. thi

. >>> celgene moving better, almost 70% now. it made its goals in regard to patients moving the blood. the stock is up more than 100% over the past year. ty? >> sue, the world's top meeting moguls and tech titans are meeting out in idaho and that's where our julia broke the news that john malone says he sees time warner cable a buyer of other cable operators in an industry that he thinks is in need of consolidation. julia joins us now with another special guest. julia? >> reporter: thanks so much, tyler, that's right, i'm joined by venture capitalist mike andreesen. thanks for joining us. >> it's good to be here. >> they are recently making billion-dollar acquisitions. is this a bubble? >> i don't think it's a bubble, i think it's a boom. i think consumers love the internet, i think advertisers are moving on line. a lot of things we were talking about for 15 years is happening in a big way now. >> you said it was a tech suppression because of the market. do you think the market is still broken? >> it's become sort of a two-class

right now, celgene is the cheapest. >> interesting. with that, the dow is down 70, and we go the bob pi ssani on a friday. hi, bob. >> going into the derek and happy friday, everybody. we were flat on the week, and the biggest thing that we had was not erp earnings, but interest rates. three days this week the 10-year yields move to the upside and three days the stocks have struggled with the dow. we are now into negative territory for the week on the s&p 500. and no great rotation. i keep watching the weekly mutual fund and etf flow numbers to e see the signs of the great rotations of the bonds into stocks, but it is not happening. we are getting sig nnificant amount of money going into the stock funds again this week, and every single week this year, but money is going back into the bond funds and june is a di s disaster, and all of the money went into money market funds. it didn't go huge into the stock market. now we are seeing the outflows into the money market funds, and inflows into the stock market funds and inflows into the bo

i get that with celgene. they announced they would be able to reapply. but gilead, nothing special at all. when we were all fretting and worrying, the two stocks are regarded as the most expensive large cap equities in the universe. amazon and netflix. now, when i was starting my old hedge fund, i used to go after these kinds of stocks. every time we had a interest rate spike, i shortened betting the price earned multiple i'd be coining money. but once rates stabilized, you were history and the shorts that did these trades this time around, they are, indeed, history. amazon, netflix, 52-week highs today. good shorts spoiled! of course, there are some stock that haven't come back. housing stocks haven't, they need mortgage rates down to get them back. but if rates go down, they will go up. blackberry, coca-cola, united parcel, more on that later. they're disappointed where they are right now. they're in, yes, indeed, the bow wow chateau. but for the bottom line, what are we thinking here? looking at recent history, we fretted too much. we worried too much

i know you love celgene. >> a little bit self-serving because it happens to be one of -- >> i'm offended and appalled that you would pest it. >> j&j, i don't know a lot about what america is going to look like in 30 years. i do know this, we're going to be older and we're more likely going to be fatter and three of the top 100 names are biotech, j&j doing well, any 20-year sector better than the aging demographic, fatter, healthier, prescription drugs for life model? >> 1985. >> i'm looking for a place to involved for the next 20 years. j jaj, medically is vices doing bet and brick growth up 19%. gorski totally delivered. >> you really think it's the ceo that makes the difference. >> i think weld owen lost his way. >> done the medicine side of money in med sit quite a lot now. what about the money side of things. i don't know whether it was lack week or the week we have. >> we have the runs that were supposed to do well at the regionals and the money center not supposed to do so well. regionals, comerica not a great bank but ming of america roars and if he do a bad, jorgan looks fantasti

celgene has a noented this and who am i that the fabulous ceo offal gene doesn't plan to sell. this is another one where if you can get a piece of the deal, i expect the first day of trading to be great, but then let the rest ride. i know, highly unusual for us, but the bioteches have been more than one-day wonders and finally there's been an intriguing one. energy, energy, yes, the big utility is doing a spin-off on wednesday. nrgy yield that i think is worth checking out. unity ipo, a youngster, utility ipos had the best week of all stocks. people now see these stocks as bond market equivalents vulnerable to interest rates rising. however, energy has held up and the stock is currently at a 52-week high and the dividend vehicle and the plan is for the company to support a 6% yield and now i can't bust this ipo on the current environment, but it is absolutely worth watch to see if the mark has saved it over the high yielders here's the bottom line. we have three sex ipos coming over the next two weeks that are worth getting a piece of that i want you in. >> buy, buy, buy. >> re

i only recognized that because celgene is down the block from me. and also because my mom died of kidney cancer, personal insight that drew me to onyx's franchise which is a break through drug for kidney cancer. which has been a death sentence for many before this. and noodle, when it started trading it hasn't looked back. it's infuriating to me. i'm blaming the fact i missed this in the parlor game of international finance. there was too much going on, i was too worried about the ten year. i knew that noodles might be the hottest concept out there. you can't get into the joint. "new york times" say the hottest trend around is noodles. i know the noodle business seems still born but the concept is a winning one. the ipo itself, hey, lost in the hand wringing over whether the fed was tightening or not. although my colleague herb greenberg does point out that noodles may not have the same store sales growth that the market is reporting. $8.73 run-up. this is a bad sign for a stock picker like me. you have to take advantage of the free money. lately it

alexion pharma up 21%, that was our mystery chart of the day and gilad and celgene up 16%, top ten in the s&p 500 this month. with those kind of gains you think anything left in the gas tank? let's ask chris raymond, a senior analyst at r.w. baird. thanks for joining us. of all the names you cover, can you, a, explain these big runs recently and, b, say if any of them are still worth buying? >> yeah, thanks, brian, thanks for having me. the two names i guess that we're focusing on specifically near term and for earnings are regeneron and alexion and absolutely i think there's guess in the tank for these to move forward. what we're calling for is sizable upgrades this quarter. >> alexion, biotech legalese, can you tell us what they do, what drugs they make had. >> quintessential business model. they have a drug called solaris which treats diseases you've never heard of, pnh and ahus, two rare diseases which make for a good business model, high profitability and almost the closest thing to an anew. if you get that patient, you have that patient for life, so, as i said, very high profit

another winner for you celgene, a late stage cancer drug improved survival. and lung cancer patients turning up with good news on that. obamacare, you've got to say it appears to be unravelling. is the mainstream media covering this unravelling? brent bozell is with us. i'm saying it's unravelling, is the media saying the same thing. >> it's falling apart and everyone knows it's going to continue to fall apart. the employer mandate postponed for a year, that tells you the thing is in shambles, it's worse than that. where is the individual mandate postponed? how can do you the employer and not the individual? that's one big question. another big question, is that constituti constitutionalists asking, what gave barack obama the ability to do that. the president doesn't have the authority, ability to do that that's a huge issue coming up above congress where senators like mike lee are going to ask that question. so there's huge calamities going on, not to mention the cost. it was projected to be under a trillion now it's over 3 trillion. not to mention the fact

names like celgene, up 90%, as well as gilead sciences. and facebook, which announced today it will allow people to easily add public posts from facebook to outside blogs and websites, that stock up some 50% in july. charging back toward that offering price of $38. a long road back. remember, the intraday low here, $17.55 back in september 2012. in the red, many of the tech names. broadcom, micron, sandisk, though stx still up some 35%. and pulte, lennar, the group has been nailed on worries about how higher mortgage rates will impact the industry, and we'll end here on bud, the beermaker, moves sharply higher today, up some 6% this month. making more money than analysts forecasted in the second quarter. fans trading up to the premium suddens. bill, back to you. >> all right, josh, thank you. yeah, the facebook move back to $38 today. i know you have a debate on that the next hour, on whether or not that can continue. or that's the peak for right now. >> we'll see. a big victory for facebook. no doubt about it. and after that earnings rele

nicole: celgene and the drug round of 70% this year. hitting an all-time high today. they will be moving forward with a new drug. gas is reporting after the bell. reporting with a new hi there. up about 1%. tesla motors has done incredibly well this year. up 1.5%. a possible takeover target for the electric cars. back to you. dagen: thank you so much, nicole. smokers, you could be catching a break. you could get relief from the penalties that will be applied to tobacco use that should result in higher premium for smokers. wayne rodgers joining us now from los angeles. it is basically a computer system problem. i think overall, this just speaks to what a disaster this health care law is. >> you are right. it is a mental problem. you have morons trying to design a plan that is impossible to design good you have over 20,000 pages of regulation. it is a nightmare. the congress does not know what they are doing. they did not read the law. it is not a computer problem. the computer problem is a minor part of the fact of you have idiots trying to devise a program that does n

. >> and we will get to celgene and bios. >> the bears will say, but crocs, crocs. yeah, i went to the playground and i got that wrong. >> when we come back, michael dell says that he is at peace and should dell shareholders feel the same way? the latest on the company's buyout battle coming up. >>> and the economist who is putting the kardashians and u.s. gdp in the same sentence. we will have him explain why he is doing that. as you listen to the musical stylings of kim kardashian, look at the futures and we will see if yesterday was the beginning of something new for the market, but the futures are down 54 and more "squawk on the street" back in a moment. >>> dell founder michael dell says that he is at peace at whatever the shareholders decide over his offer to take the company profit. in the letter to shareholderings he repeated that the current voting rules are unfair and should be changed. the rules say that the shares not voted and this is the delaware standard, essentially counts as votes against the going private transaction, because you need a majority of

this is a celgene, bioagain, do we have -- buy. >> slv? >> this was the best quarter of the year so far. everything is good. >> barclays further. >> he says don't worry about it, but this stock is a real dog. i would not make a stand here. >> would you make a stand here with the s&p at some of these lofty levels, given what we are hearing from some big players in corporate, america? >> it's a big industrial company base that's selling overseas. i think europe is turning, and that's what these companies are saying. if it's international and industrial, it's a win. keep that in mind. >> what about consumer stocks, the ones that having rallies all year long? >> i think people felt disappointed by kimberly, but then again chipotle, wow, what a great quarter, so it's mixed. chipotle should not be sold here. >> of all the names coming. facebook -- something that you really want to hear from in particular? >> i have to say, i want to hear from netflix. why do we care about netflix? this is one of the thor rare instances, which like what you watch

we talked to jim cramer about it whether it is celgene or gilead, and interesting, and we will see if there is more consolidation. i want to hear about the calls going on for merck and pfizerings because i nknow that the news is coming awe of those as well. should we get to it? get to the analysts to see what they have the say about it and get more insight on the big pharma. tony butler is at barclays, and seamus fernandez is at leering swan, an analyst. and thank you both. t tony, let me start with you, if i could get your fake on merck he here. i am looking at something in the conference call they said that operational x januvial is up, and anything come off of the conference call better than expected? >> well, that may have been the focus for the street, but q1 sales were dismal for a large driver to merck's revenue, and you are talking about a product or two products under $36 billion in sales so based on the comments earlier, the period that merck is undergoing, they need the products to do well. q tlt 1 is dismal and picked it up in q2 and the u.s. is about 5% growth. they need